3 results match your criteria: "Nanjing Tianyinshan Hospital of China Pharmaceutical University[Affiliation]"
Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial - Author's reply.
Lancet
October 2024
Nanjing Tianyinshan Hospital of China Pharmaceutical University, Nanjing 211100, China. Electronic address:
SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer.
Cancer Immunol Immunother
September 2024
GI Cancer Center, Nanjing Tianyinshan Hospital of China Pharmaceutical University, Gulou, Nanjing, Jiangsu, China.
Article Synopsis
- Sitravatinib is a targeted treatment for advanced cancers, specifically focusing on TAM receptors and others, and was tested in a study (SAFFRON-104) for its effectiveness alone or with another drug (tislelizumab) in advanced liver or stomach cancers.
- The study included 111 patients, and the recommended dosage of sitravatinib was established at 120 mg daily. Results showed that about 25% of patients experienced a positive response to sitravatinib alone, while those receiving it with tislelizumab had lower response rates.
- Overall, the combination of sitravatinib and tislelizumab was generally safe with manageable side effects, indicating preliminary
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.
Lancet
December 2023
Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Background: Evidence for the efficacy of combined PD-1 and HER2 blockade with chemotherapy on progression-free and overall survival in HER2-positive gastro-oesophageal cancer is scarce. The first interim analysis of the randomised, phase 3 KEYNOTE-811 study showed a superior objective response with pembrolizumab compared with placebo when added to trastuzumab plus fluoropyrimidine and platinum-based chemotherapy. Here, we report results from protocol-specified subsequent interim analyses of KEYNOTE-811.
View Article and Find Full Text PDF